Chimerix Appoints Marc D. Kozin to Board of Directors
March 21 2024 - 7:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission
is to develop medicines that meaningfully improve and extend the
lives of patients facing deadly diseases, today announced the
appointment of Marc D. Kozin as the newest member of the Company’s
Board of Directors. In addition, Patrick Machado has announced his
retirement from the Chimerix Board effective at the Company’s 2024
Annual Meeting of Stockholders in June, after ten years of service.
“We are pleased to welcome Marc to the Board of Directors.
Marc’s strategic insights and leadership will undoubtedly
contribute to the continued growth and success of Chimerix as we
work to advance our pipeline to commercialization,” said Mike
Andriole, Chief Executive Officer of Chimerix. “We extend our
gratitude to Pat for his exceptional service and unwavering
dedication to Chimerix. His leadership and guidance have been
instrumental in our achievements over the past decade. We wish him
continued success in all his endeavors.”
Mr. Kozin brings more than 35 years of experience in corporate
and business strategy consulting, merger and acquisition advisory
services, and value management. Mr. Kozin previously served as
President of L.E.K., a global strategy consulting firm, where he
established the Boston office and led the development of the firm’s
industry leading life science strategic planning practice. He
currently serves on the Board of Directors of UFP Technologies
(NASDAQ: UFPT) and HCRx Holdings.
Mr. Kozin holds a B.A. in Economics from Duke University and an
M.B.A. from The Wharton School, University of Pennsylvania.
About Chimerix Chimerix is a biopharmaceutical
company with a mission to develop medicines that meaningfully
improve and extend the lives of patients facing deadly diseases.
The Company’s most advanced clinical-stage development program,
ONC201, is in development for H3 K27M-mutant glioma.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that are subject
to risks and uncertainties that could cause actual results to
differ materially from those projected. Forward-looking statements
include those relating to, among other things, Chimerix’s continued
growth and success and the advancement of its product pipeline.
Among the factors and risks that could cause actual results to
differ materially from those indicated in the forward-looking
statements are risks related to the timing, completion and outcome
of the Phase 3 ACTION study of ONC201; risks associated with
repeating positive results obtained in prior preclinical or
clinical studies in future studies; risks related to the clinical
development of ONC206; and additional risks set forth in the
Company's filings with the Securities and Exchange Commission.
These forward-looking statements represent the Company's judgment
as of the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking
statements.
CONTACT:Will O’ConnorStern Investor
Relations212-362-1200ir@chimerix.com
Ufp Technologies (NASDAQ:UFPT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Ufp Technologies (NASDAQ:UFPT)
Historical Stock Chart
From Aug 2023 to Aug 2024